2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, hydronephrosis, infiltrating bladder urothelial carcinoma sarcomatoid variant, kidney disorder, kidney pelvis sarcomatoid transitional cell carcinoma, micropapillary variant infiltrating bladder urothelial carcinoma, neoplasm, plasmacytoid variant infiltrating bladder urothelial carcinoma, renal pelvis urothelial carcinoma, ureter cancer, ureter transitional cell carcinoma, ureteral disorder, urethra neoplasm, urethra transitional cell carcinoma, urethral disorder, urinary system disorderActive, not recruitingEarly phase 12026-09-14NCT02812420
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerNeoplasms by Histologic Type, carcinoma, epithelial neoplasm, infiltrating bladder urothelial carcinoma sarcomatoid variant, micropapillary variant infiltrating bladder urothelial carcinoma, neoplasm, plasmacytoid variant infiltrating bladder urothelial carcinoma, transitional cell carcinomaActive, not recruitingPhase 22026-07-16NCT03744793